As of Q1'26 (2025-09-30), AFRM reported R&D Expenses of 168.1M USD and SG&A Expenses of 223.4M USD, representing the latest available data points for each category. This marks an increase in both expense categories compared to the previous quarter, with R&D rising from 154.6M USD and SG&A from 212.4M USD. Over the period from Q3'23 to Q1'26, both R&D and SG&A expenses have exhibited notable fluctuations. R&D Expenses initially declined from 161.8M USD in Q3'23 to a low of 119.8M USD in Q2'24 before steadily climbing to 168.1M USD by Q1'26. SG&A Expenses showed a similar pattern, decreasing from 280.2M USD in Q3'23 to 258.8M USD in Q4'24, followed by a dip to 208.3M USD in Q3'25, and then rebounding to 223.4M USD in Q1'26. Overall, the chart indicates a period of expense optimization followed by renewed growth in both operating expense categories.